FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen ® / Procrit® across all indications
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company's proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S. FDA Advisory Committee.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
More News: Cancer & Oncology | Epogen | Food and Drug Administration (FDA) | Pfizer | Pharmaceuticals | Procrit